Targeted therapy versus non-targeted therapy in renal cell carcinoma patients.

This real-world cohort study utilized the Taiwan National Health Insurance Research Database and Cancer Registry to evaluate 14,131 renal cell carcinoma cases diagnosed between 1998 and 2016. The analysis compared outcomes between patients receiving targeted therapy and those receiving non-targeted therapy, with follow-up extending through lifetime. Cumulative incidence rates for RCC increased over the study period, rising from 0.37% to 0.73% in men and from 0.23% to 0.36% in women. In patients under 50 years of age, the loss of life expectancy was 14.38 years for men and 12.89 years for women.

Regarding advanced cases, life expectancy was 4.43 years for patients on targeted therapy versus 3.63 years for those on non-targeted therapy. However, the loss of life expectancy between these two groups was reported as similar. No data on adverse events, serious adverse events, discontinuations, or tolerability were reported in this study. Additionally, absolute numbers, p-values, or confidence intervals were not provided for the primary comparisons.

The study suggests suboptimal efficiency under current clinical practice. Key limitations include the lack of reported safety data and the absence of specific statistical measures for the primary outcomes. The practice relevance indicates a need to re-evaluate reimbursement strategies by considering pharmacogenomic heterogeneity, implementing genomic profiling for precision medicine, and transitioning toward more effective combination therapy paradigms. These observations are based on observational data and do not establish causality.